Advaxis Inc Webinar in Biotech and Specialty Pharma Hosted By Alliance Global Partners Transcript
All right. Well, thank you, everyone. Good morning, everyone. It's my pleasure to welcome you all to AGP's Grand Rounds, our webinar series in biotechnology and specialty pharma. My name is James Molloy. I'm the biotech and specialty pharma analyst here at Alliance Global Partners.
Now before we go any further, I'd just like to point to our disclosure slide; if Elisa can put that up, please, for the relevant disclosures for today's webinar. And the format of today's Grand Rounds webinar will be a 45-minute to maximum 60-minutes fireside chat format with our guests, who I'll be asking a series of questions to the management of Advaxis, which trades on the NASDAQ as ADXS. We'll use the next 45 minutes or so to go over their story and the new developments at the company. (Operator Instructions)
Advaxis is a clinical-stage biotech company. It's developing cancer immunotherapies based on the company's proprietary Lm-based antigen
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
